Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments

Lina Quteineh; Frederik Vandenberghe; Nuria Saigi Morgui; Aurélie Delacrétaz; Eva Choong; Mehdi Gholam-Rezaee; Pierre J. Magistretti; Guido Bondolfi; Armin Von Gunten; Martin A. Preisig; Enrique Castelao; Peter Vollenweider; Gérard Waeber; Murielle Bochud; Zoltán Kutalik; Philippe O. Conus; Chin Bin Eap

doi:10.1097/FPC.0000000000000131

Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments

Lina Quteineh, Frederik Vandenberghe, Nuria Saigi Morgui, Aurélie Delacrétaz, Eva Choong, Mehdi Gholam-Rezaee, Pierre J. Magistretti, Guido Bondolfi, Armin Von Gunten, Martin A. Preisig, Enrique Castelao, Peter Vollenweider, Gérard Waeber, Murielle Bochud, Zoltán Kutalik, Philippe O. Conus, Chin Bin Eap

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

Background Metabolic syndrome (MetS) associated with psychiatric disorders and psychotropic treatments represents a major health issue. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme that catalyzes tissue regeneration of active cortisol from cortisone. Elevated enzymatic activity of 11β-HSD1 may lead to the development of MetS. Methods We investigated the association between seven HSD11B1 gene (encoding 11β-HSD1) polymorphisms and BMI and MetS components in a psychiatric sample treated with potential weight gain-inducing psychotropic drugs (n=478). The polymorphisms that survived Bonferroni correction were analyzed in two independent psychiatric samples (n R1 =168, n R2 =188) and in several large population-based samples (n 1 =5338; n 2 =123 865; n 3 >100 000). Results HSD11B1 rs846910-A, rs375319-A, and rs4844488-G allele carriers were found to be associated with lower BMI, waist circumference, and diastolic blood pressure compared with the reference genotype (P corrected

Original language	English (US)
Pages (from-to)	246-258
Number of pages	13
Journal	Pharmacogenetics and Genomics
Volume	25
Issue number	5
DOIs	https://doi.org/10.1097/FPC.0000000000000131
State	Published - Mar 9 2015

Bibliographical note

KAUST Repository Item: Exported on 2020-10-01
Acknowledgements: This work has been funded in part by the Swiss National Research Foundation (CBE and PC: 324730_144064). C.B.E. has received research support from Takeda and from the Roche Organ Transplantation Research Foundation in the past 3 years. M.B. is supported by the Swiss School of Public Health Plus (SSPH+). P.V. and G.W. received an unrestricted grant from GlaxoSmithKline to build the CoLaus study. The CoLaus/PsyCoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (105993, 118308, 122661, 139468). Z.K. received support from the Leenaards Foundation and the Swiss National Science Foundation (31003A-143914).

ASJC Scopus subject areas

Genetics
Molecular Medicine
Molecular Biology
Genetics(clinical)

Access to Document

10.1097/FPC.0000000000000131

Cite this

Quteineh, L., Vandenberghe, F., Saigi Morgui, N., Delacrétaz, A., Choong, E., Gholam-Rezaee, M., Magistretti, P. J., Bondolfi, G., Von Gunten, A., Preisig, M. A., Castelao, E., Vollenweider, P., Waeber, G., Bochud, M., Kutalik, Z., Conus, P. O., & Eap, C. B. (2015). Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments. Pharmacogenetics and Genomics, 25(5), 246-258. https://doi.org/10.1097/FPC.0000000000000131

@article{0d1257efd39549c889324b0a45eb357b,

title = "Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments",

abstract = "Background Metabolic syndrome (MetS) associated with psychiatric disorders and psychotropic treatments represents a major health issue. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme that catalyzes tissue regeneration of active cortisol from cortisone. Elevated enzymatic activity of 11β-HSD1 may lead to the development of MetS. Methods We investigated the association between seven HSD11B1 gene (encoding 11β-HSD1) polymorphisms and BMI and MetS components in a psychiatric sample treated with potential weight gain-inducing psychotropic drugs (n=478). The polymorphisms that survived Bonferroni correction were analyzed in two independent psychiatric samples (n R1 =168, n R2 =188) and in several large population-based samples (n 1 =5338; n 2 =123 865; n 3 >100 000). Results HSD11B1 rs846910-A, rs375319-A, and rs4844488-G allele carriers were found to be associated with lower BMI, waist circumference, and diastolic blood pressure compared with the reference genotype (P corrected",

author = "Lina Quteineh and Frederik Vandenberghe and {Saigi Morgui}, Nuria and Aur{\'e}lie Delacr{\'e}taz and Eva Choong and Mehdi Gholam-Rezaee and Magistretti, {Pierre J.} and Guido Bondolfi and {Von Gunten}, Armin and Preisig, {Martin A.} and Enrique Castelao and Peter Vollenweider and G{\'e}rard Waeber and Murielle Bochud and Zolt{\'a}n Kutalik and Conus, {Philippe O.} and Eap, {Chin Bin}",

note = "KAUST Repository Item: Exported on 2020-10-01 Acknowledgements: This work has been funded in part by the Swiss National Research Foundation (CBE and PC: 324730_144064). C.B.E. has received research support from Takeda and from the Roche Organ Transplantation Research Foundation in the past 3 years. M.B. is supported by the Swiss School of Public Health Plus (SSPH+). P.V. and G.W. received an unrestricted grant from GlaxoSmithKline to build the CoLaus study. The CoLaus/PsyCoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (105993, 118308, 122661, 139468). Z.K. received support from the Leenaards Foundation and the Swiss National Science Foundation (31003A-143914).",

year = "2015",

month = mar,

day = "9",

doi = "10.1097/FPC.0000000000000131",

language = "English (US)",

volume = "25",

pages = "246--258",

journal = "Pharmacogenetics and Genomics",

issn = "1744-6872",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

Quteineh, L, Vandenberghe, F, Saigi Morgui, N, Delacrétaz, A, Choong, E, Gholam-Rezaee, M, Magistretti, PJ, Bondolfi, G, Von Gunten, A, Preisig, MA, Castelao, E, Vollenweider, P, Waeber, G, Bochud, M, Kutalik, Z, Conus, PO & Eap, CB 2015, 'Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments', Pharmacogenetics and Genomics, vol. 25, no. 5, pp. 246-258. https://doi.org/10.1097/FPC.0000000000000131

TY - JOUR

T1 - Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments

AU - Quteineh, Lina

AU - Vandenberghe, Frederik

AU - Saigi Morgui, Nuria

AU - Delacrétaz, Aurélie

AU - Choong, Eva

AU - Gholam-Rezaee, Mehdi

AU - Magistretti, Pierre J.

AU - Bondolfi, Guido

AU - Von Gunten, Armin

AU - Preisig, Martin A.

AU - Castelao, Enrique

AU - Vollenweider, Peter

AU - Waeber, Gérard

AU - Bochud, Murielle

AU - Kutalik, Zoltán

AU - Conus, Philippe O.

AU - Eap, Chin Bin

N1 - KAUST Repository Item: Exported on 2020-10-01 Acknowledgements: This work has been funded in part by the Swiss National Research Foundation (CBE and PC: 324730_144064). C.B.E. has received research support from Takeda and from the Roche Organ Transplantation Research Foundation in the past 3 years. M.B. is supported by the Swiss School of Public Health Plus (SSPH+). P.V. and G.W. received an unrestricted grant from GlaxoSmithKline to build the CoLaus study. The CoLaus/PsyCoLaus study received financial contributions from GlaxoSmithKline, the Faculty of Biology and Medicine of Lausanne, the Swiss National Science Foundation (105993, 118308, 122661, 139468). Z.K. received support from the Leenaards Foundation and the Swiss National Science Foundation (31003A-143914).

PY - 2015/3/9

Y1 - 2015/3/9

N2 - Background Metabolic syndrome (MetS) associated with psychiatric disorders and psychotropic treatments represents a major health issue. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme that catalyzes tissue regeneration of active cortisol from cortisone. Elevated enzymatic activity of 11β-HSD1 may lead to the development of MetS. Methods We investigated the association between seven HSD11B1 gene (encoding 11β-HSD1) polymorphisms and BMI and MetS components in a psychiatric sample treated with potential weight gain-inducing psychotropic drugs (n=478). The polymorphisms that survived Bonferroni correction were analyzed in two independent psychiatric samples (n R1 =168, n R2 =188) and in several large population-based samples (n 1 =5338; n 2 =123 865; n 3 >100 000). Results HSD11B1 rs846910-A, rs375319-A, and rs4844488-G allele carriers were found to be associated with lower BMI, waist circumference, and diastolic blood pressure compared with the reference genotype (P corrected

AB - Background Metabolic syndrome (MetS) associated with psychiatric disorders and psychotropic treatments represents a major health issue. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) is an enzyme that catalyzes tissue regeneration of active cortisol from cortisone. Elevated enzymatic activity of 11β-HSD1 may lead to the development of MetS. Methods We investigated the association between seven HSD11B1 gene (encoding 11β-HSD1) polymorphisms and BMI and MetS components in a psychiatric sample treated with potential weight gain-inducing psychotropic drugs (n=478). The polymorphisms that survived Bonferroni correction were analyzed in two independent psychiatric samples (n R1 =168, n R2 =188) and in several large population-based samples (n 1 =5338; n 2 =123 865; n 3 >100 000). Results HSD11B1 rs846910-A, rs375319-A, and rs4844488-G allele carriers were found to be associated with lower BMI, waist circumference, and diastolic blood pressure compared with the reference genotype (P corrected

UR - http://hdl.handle.net/10754/563963

UR - http://journals.lww.com/01213011-201505000-00004

UR - http://www.scopus.com/inward/record.url?scp=84928226410&partnerID=8YFLogxK

U2 - 10.1097/FPC.0000000000000131

DO - 10.1097/FPC.0000000000000131

M3 - Article

C2 - 25751397

SN - 1744-6872

VL - 25

SP - 246

EP - 258

JO - Pharmacogenetics and Genomics

JF - Pharmacogenetics and Genomics

IS - 5

ER -

Impact of HSD11B1 polymorphisms on BMI and components of the metabolic syndrome in patients receiving psychotropic treatments

Abstract

Bibliographical note

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this